S&P 500   3,013.19 (+0.22%)
DOW   26,858.98 (+0.12%)
QQQ   193.81 (+0.22%)
FB   189.52 (-0.13%)
MSFT   139.35 (+0.66%)
GOOGL   1,246.61 (+0.19%)
AMZN   1,780.19 (-0.31%)
MU   45.05 (-0.38%)
T   38.12 (-0.29%)
ACB   3.58 (-2.99%)
NFLX   269.33 (-3.14%)
GILD   66.02 (+1.24%)
DIS   132.85 (+1.99%)
S&P 500   3,013.19 (+0.22%)
DOW   26,858.98 (+0.12%)
QQQ   193.81 (+0.22%)
FB   189.52 (-0.13%)
MSFT   139.35 (+0.66%)
GOOGL   1,246.61 (+0.19%)
AMZN   1,780.19 (-0.31%)
MU   45.05 (-0.38%)
T   38.12 (-0.29%)
ACB   3.58 (-2.99%)
NFLX   269.33 (-3.14%)
GILD   66.02 (+1.24%)
DIS   132.85 (+1.99%)
Log in

Invion Stock Price, News & Analysis (ASX:IVX)

A$0.01
0.00 (0.00 %)
(As of 10/22/2019 10:54 AM ET)
Today's Range
A$0.01
Now: A$0.01
A$0.01
50-Day Range
A$0.01
MA: A$0.02
A$0.02
52-Week Range
A$0.01
Now: A$0.01
A$0.03
Volume35,217 shs
Average VolumeN/A
Market Capitalization$77.01 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Invion Limited, a clinical-stage drug development company, develops treatments for chronic inflammatory and autoimmune diseases in Australia and the United States. Its drug candidates in phase II clinical trials include INV102, a beta blocker to treat chronic inflammatory airway diseases, such as asthma and chronic obstructive pulmonary disease; and INV104, a leukotriene receptor antagonist that reduces inflammation, constriction of the airways, and build-up of mucus in the lungs. The company has a research and development alliance agreement with Hudson Institute of Medical Research to collaborate on a range of research and development projects for the Photosoft technology for the treatment of a range of cancers. Invion Limited is based in East Kew, Australia.

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone61 3 9081 6005

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.88 million
Cash FlowA$0.00 per share
Book ValueA$0.00 per share

Profitability

Miscellaneous

EmployeesN/A
Outstanding Shares5,500,610,048
Market Cap$77.01 million
Next Earnings DateN/A
OptionableNot Optionable

Receive IVX News and Ratings via Email

Sign-up to receive the latest news and ratings for IVX and its competitors with MarketBeat's FREE daily newsletter.


Invion (ASX:IVX) Frequently Asked Questions

What is Invion's stock symbol?

Invion trades on the ASX under the ticker symbol "IVX."

Has Invion been receiving favorable news coverage?

Media coverage about IVX stock has been trending somewhat negative on Tuesday, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Invion earned a daily sentiment score of -1.3 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Invion.

Who are some of Invion's key competitors?

What other stocks do shareholders of Invion own?

Who are Invion's key executives?

Invion's management team includes the folowing people:
  • Dr. Gregory Royce Collier, MD, CEO & Exec. Director (Age 60)
  • Ms. Melanie Farris, Head of Operations & Company Sec.
  • Dr. Mitchell Glass, Exec. VP of R&D, Chief Medical Officer and Exec. Director (Age 66)
  • Mr. Tom Coogan, Consultant
  • Dr. Dean Naylor, Head of Intellectual Property Devel.

What is Invion's stock price today?

One share of IVX stock can currently be purchased for approximately A$0.01.

How big of a company is Invion?

Invion has a market capitalization of $77.01 million and generates $3.88 million in revenue each year. View Additional Information About Invion.

What is Invion's official website?

The official website for Invion is http://www.inviongroup.com/.

How can I contact Invion?

The company can be reached via phone at 61 3 9081 6005.


MarketBeat Community Rating for Invion (ASX IVX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  11 (Vote Outperform)
Underperform Votes:  11 (Vote Underperform)
Total Votes:  22
MarketBeat's community ratings are surveys of what our community members think about Invion and other stocks. Vote "Outperform" if you believe IVX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IVX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/22/2019 by MarketBeat.com Staff

Featured Article: Forex

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel